Angiotensin II antagonists DuP 753 and TCV 116.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Hypertension - Supplement

• Publication date

  1994-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 7884581
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of anti-angiotensin II on blood pressure and sensitivity to angiotensin and renin. Studies on normal, nephrectomized, ureterligated, continuously angiotensin infused, and renal hypertensive rats.

  2009cited by this paper
• Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

  2004cited by this paper
• Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

  1993cited by this paper
• Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.

  1993cited by this paper
• Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.

  1993cited by this paper
• Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

  1992cited by this paper
• Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.

  1992cited by this paper
• In vitro pharmacology of DuP 753.

  1991cited by this paper
• Angiotensin II receptor heterogeneity.

  1991cited by this paper
• Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II

  1991cited by this paper
• In vivo pharmacology of DuP 753.

  1991cited by this paper
• Angiotensin II receptor antagonist markedly reduces mortality in salt-loaded Dahl S rats.

  1991cited by this paper
• Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: studies in isolated perfused hydronephrotic kidneys.

  1991cited by this paper
• DuP 753 is a potent nonpeptide antagonist of angiotensin II receptors in isolated perfused rat kidney and cultured renal cells.

  1991cited by this paper
• The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists.

  1991cited by this paper
• Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs.

  1991cited by this paper
• DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet.

  1991cited by this paper
• Effects of DuP 753 on renal function of normotensive and spontaneously hypertensive rats.

  1991cited by this paper
• Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure.

  1991cited by this paper
• Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.

  1990cited by this paper
• Noninvasive Blood Pressure Monitoring at the Finger for Studying Short Lasting Pressor Responses in Man

  1990cited by this paper
• Non-peptide angiotensin II receptor antagonists. II. Pharmacology of S-8308.

  1988cited by this paper
• The present molecules of converting enzyme inhibitors.

  1985cited by this paper
• Role of Reactive Hyperreninemia in Blood Pressure Changes Induced by Sodium Depletion in Patients with Refractory Hypertension

  1981cited by this paper
• Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade.

  1978cited by this paper
• Angiotensin II blockade in normal man: interaction of renin and sodium in maintaining blood pressure.

  1977cited by this paper
• Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;.

  1975cited by this paper
• Malignant Hypertension Resulting from Deoxycorticosterone Acetate and Salt Excess: ROLE OF RENIN AND SODIUM IN VASCULAR CHANGES

  1975cited by this paper
• Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulation.

  1974cited by this paper
• Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure.

  1973cited by this paper
• Angiotensin-Sodium Interaction in Blood Pressure Maintenance of Renal Hypertensive and Normotensive Rats

  1973cited by this paper
• A Specific Competitive Antagonist of the Vascular Action of Angiotensin II

  1971cited by this paper
• Hypertension of Renal Origin: Evidence for Two Different Mechanisms

  1971cited by this paper
• A specific competitive inhibitor of angiotensin II.

  1970cited by this paper

• Angiotensin II Receptor Antagonists

  2005cites this paper
• New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia

  2005cites this paper
• THERAPEUTIC EFFECTS OF ANGIOTENSIN II INHIBITION OR BLOCKADE ON THE PROGRESSION OF CHRONIC RENAL DISEASE

  2003cites this paper
• Routine renin-angiotensin system blockade in renal transplantation?

  2002cites this paper
• Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients

  2000cites this paper
• Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension.

  1999cites this paper
• Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.

  1998cites this paper
• Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.

  1998cites this paper
• Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.

  1998cites this paper
• Angiotensin II receptor antagonists and treatment of hypertension and renal disease

  1998cites this paper
• ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKADE: A NEW DEVELOPMENT IN CARDIOVASCULAR PHARMACOLOGY

  1998cites this paper
• The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.

  1997cites this paper
• Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries.

  1997cites this paper
• Angiotensin receptors and their antagonists.

  1996cites this paper
• Angiotensin receptor antagonists: focus on losartan.

  1995cites this paper